Tasly Pharmaceutical Group Co Ltd (600535) — Cash Flow-to-Debt Ratio
Tasly Pharmaceutical Group Co Ltd (600535) has a Cash Flow-to-Debt Ratio of 0.20x as of December 2025, meaning its operating cash flow of CN¥552.13 Million could theoretically repay 0% of its total liabilities (CN¥2.79 Billion) in one year. See 600535 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tasly Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2001–2025)
Historical debt coverage capacity for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. For the full cash flow conversion analysis, see Tasly Pharmaceutical Group Co Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year debt coverage analysis for Tasly Pharmaceutical Group Co Ltd. Check 600535 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -27.4% |
| 2024 | 0.70x | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +9.9% |
| 2023 | 0.64x | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +6.4% |
| 2022 | 0.60x | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -30.7% |
| 2021 | 0.87x | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +99.1% |
| 2020 | 0.44x | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +215.2% |
| 2019 | 0.14x | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +29.3% |
| 2018 | 0.11x | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +263.3% |
| 2017 | -0.07x | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -150.6% |
| 2016 | 0.13x | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +193.2% |
| 2015 | 0.04x | CN¥340.00 Million | CN¥7.71 Billion | ▼ -43.8% |
| 2014 | 0.08x | CN¥616.76 Million | CN¥7.85 Billion | ▲ +37.7% |
| 2013 | 0.06x | CN¥346.17 Million | CN¥6.07 Billion | ▼ -54.7% |
| 2012 | 0.13x | CN¥413.31 Million | CN¥3.28 Billion | ▲ +166.6% |
| 2011 | 0.05x | CN¥135.14 Million | CN¥2.86 Billion | ▼ -75.7% |
| 2010 | 0.19x | CN¥395.05 Million | CN¥2.03 Billion | ▼ -9.8% |
| 2009 | 0.22x | CN¥400.39 Million | CN¥1.85 Billion | ▲ +12.5% |
| 2008 | 0.19x | CN¥260.21 Million | CN¥1.36 Billion | ▼ -3.0% |
| 2007 | 0.20x | CN¥221.55 Million | CN¥1.12 Billion | ▲ +116.8% |
| 2006 | 0.09x | CN¥140.56 Million | CN¥1.54 Billion | ▼ -49.5% |
| 2005 | 0.18x | CN¥214.90 Million | CN¥1.19 Billion | ▼ -26.5% |
| 2004 | 0.25x | CN¥203.27 Million | CN¥826.42 Million | ▲ +140.0% |
| 2003 | 0.10x | CN¥59.00 Million | CN¥575.74 Million | ▼ -87.4% |
| 2002 | 0.81x | CN¥206.22 Million | CN¥253.70 Million | ▲ +237.9% |
| 2001 | 0.24x | CN¥83.77 Million | CN¥348.19 Million | — |